Literature DB >> 2863387

Beta-adrenergic function in heart muscle disease and heart failure.

M R Bristow, N E Kantrowitz, R Ginsburg, M B Fowler.   

Abstract

Using data derived from clinical and experimental observations, we examine the role of the myocardial beta-adrenergic receptor system in pathophysiologic processes involved in heart muscle disease and heart failure. The available data suggest that the sympathetic nervous system exerts important influences on myocardial structure and function. As such the beta-adrenergic pathways represents an obvious locus for therapeutic intervention in evolving cardiomyopathic states.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2863387     DOI： 10.1016/0022-2828(85)90007-0

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN： 0022-2828            Impact factor:   5.000


  37 in total

1.  Distinct down-regulation of cardiac beta 1- and beta 2-adrenoceptors in different human heart diseases.

Authors:  M Steinfath; B Geertz; W Schmitz; H Scholz; A Haverich; I Breil; P Hanrath; C Reupcke; M Sigmund; H B Lo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

2.  Myocardial beta-adrenoceptor density and the distribution of beta 1- and beta 2-adrenoceptor subpopulations in children with congenital heart disease.

Authors:  R Kozlik; H H Kramer; H Wicht; A Krian; J Ostermeyer; D Reinhardt
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

Review 3.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 4.  GRK mythology: G-protein receptor kinases in cardiovascular disease.

Authors:  Gerald W Dorn
Journal:  J Mol Med (Berl)       Date:  2009-02-20       Impact factor: 4.599

5.  Carvedilol tratment of chronic heart failure: a new era.

Authors:  M Bristow
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

6.  Role of H2O2 in changing beta-adrenoceptor and adenylyl cyclase in ischemia-reperfused hearts.

Authors:  S Persad; V Panagia; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

7.  Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment.

Authors:  M C Michel; A Pingsmann; J J Beckeringh; H R Zerkowski; N Doetsch; O E Brodde
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

8.  Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors.

Authors:  E A Dubois; G A Somsen; J C van den Bos; A G Janssen; G J Boer; H D Batink; E A van Royen; M Pfaffendorf; P A van Zwieten
Journal:  J Nucl Cardiol       Date:  1996 May-Jun       Impact factor: 5.952

9.  Positive inotropic stimulation in the normal and insufficient human myocardium.

Authors:  E Erdmann; M Böhm
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

10.  Persistent increases in Ca(2+) influx through Cav1.2 shortens action potential and causes Ca(2+) overload-induced afterdepolarizations and arrhythmias.

Authors:  Xiaoying Zhang; Xiaojie Ai; Hiroyuki Nakayama; Biyi Chen; David M Harris; Mingxin Tang; Yuping Xie; Christopher Szeto; Yingxin Li; Ying Li; Hongyu Zhang; Andrea D Eckhart; Walter J Koch; Jeffery D Molkentin; Xiongwen Chen
Journal:  Basic Res Cardiol       Date:  2015-11-26       Impact factor: 17.165
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.